PHASE 3 TRIALS OF PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY (DR) WITH OR WITHOUT DIABETIC MACULAR EDEMA (DME)

被引：0
|
作者：
Cooper, B. [1 ]
Chang, M. [2 ]
Smith, R. [3 ]
Malhotra, V. [3 ]
Latkany, P. [3 ]
机构：
[1] Retina Associates LLC, Ophthalmol, Lenexa, KS USA
[2] Retinal Consultants, Ophthalmol, Sacramento, CA USA
[3] Genentech Inc, Ophthalmol, San Francisco, CA USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2022年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP249 / #4
引用
收藏
页码：A185 / A185
页数：1
相关论文
共 50 条
  • [1] Port Delivery System with Ranibizumab (PDS) in Diabetic Retinopathy (DR) with or without Diabetic Macular Edema (DME)
    Chang, Margaret
    Bobbala, Ashwini
    Malhotra, Varun
    Latkany, Paul
    DIABETES, 2021, 70
  • [2] Port Delivery System with ranibizumab (PDS) stabilizes retinal nonperfusion and macular leakage: results from Pagoda and Pavilion phase 3 trials in diabetic macular edema (DME) and diabetic retinopathy (DR)
    Wirthlin, Robert
    Gill, Manjot
    Howard, Dena
    Menezes, Alicia
    Rahman, Salman
    Latkany, Paul
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [3] Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema
    Antoszyk, Andrew N.
    Tarnowski, Kathleen Wade
    Basu, Karen
    Ehrlich, Jason S.
    Haskova, Zdenka
    OPHTHALMOLOGY RETINA, 2020, 4 (10): : 1034 - 1036
  • [4] Port delivery system with ranibizumab in the treatment of diabetic retinopathy without center-involved diabetic macular edema: primary analysis results of the phase 3 Pavilion trial
    Emanuelli, Andres
    Holekamp, Nancy
    Latkany, Paul
    Brittain, Christopher
    Howard, Dena
    Santhanakrishnan, Anjana
    Wetzel-Smith, Monica
    Quezada-Ruiz, Carlos
    Malhotra, Varun
    Pieramici, Dante
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [5] Port Delivery System With Ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 Pagoda trial
    Malhotra, Varun
    Klufas, Michael A.
    Marcus, Dennis M.
    Graff, Jordan M.
    Campochiaro, Peter A.
    Rahman, Salman
    Latkany, Paul
    Gune, Shamika
    DeGraaf, Stephanie
    Bobbala, Ashwini
    Rabena, Mel
    Ruiz, Carlos
    Khanani, Arshad M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [6] Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial
    Pieramici, Dante J.
    Awh, Carl C.
    Chang, Margaret
    Emanuelli, Andres
    Holekamp, Nancy M.
    Hu, Allen Y.
    Suner, Ivan J.
    Wykoff, Charles C.
    Brittain, Christopher
    Howard, Dena
    Quezada-Ruiz, Carlos
    Santhanakrishnan, Anjana
    Latkany, Paul
    JAMA OPHTHALMOLOGY, 2025,
  • [7] DEMOGRAPHIC, PAYER, AND CLINICAL CHARACTERISTICS OF PATIENTS RECEIVING BEVACIZUMAB (BEV) AND RANIBIZUMAB (RAN) FOR TREATMENT OF DIABETIC RETINOPATHY (DR) AND DIABETIC MACULAR EDEMA (DME)
    Chung, J.
    Radtchenko, J.
    Nero, D.
    Nabhan, C.
    Kish, J.
    Feinberg, B.
    VALUE IN HEALTH, 2018, 21 : S243 - S243
  • [8] Demographic, medical and visual aspects of Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME) in South African diabetic patients
    Sukha, Anusha Y.
    Rubin, Alan
    AFRICAN VISION AND EYE HEALTH JOURNAL, 2009, 68 (02): : 70 - 81
  • [9] Ranibizumab: A Review of Its Use in the Treatment of Diabetic Retinopathy in Patients With Diabetic Macular Edema
    Akiyode, Oluwaranti
    Dunkelly-Allen, Nikeshia
    JOURNAL OF PHARMACY TECHNOLOGY, 2016, 32 (01) : 22 - 28
  • [10] INTRAVITREAL RANIBIZUMAB FOR MACULAR EDEMA IN PATIENTS WITH DIFFERENT DIABETIC RETINOPATHY SEVERITY
    Guclu, H.
    Ozal, S. A.
    Gurlu, V. P.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2015, 25 (03) : E25 - E26
12345